The Office for Life Sciences (OLS) is a joint unit between the Department of Health & Social Care (DHSC) and Department for Business, Energy & Industrial Strategy (BEIS).
Medilink shares this bulletin with its members and networks, aimed to keep the life sciences sector up to date on the latest guidance whilst the UK is in the transition period and during the Coronavirus (COVID-19) outbreak.
This week’s edition includes:
- Request for Marketing Authorisation Holders (MAHs) volunteers to test new medicine supply reporting system
- Guidance from MHRA
NEW – MHRA launched a new reporting site for any suspected adverse drug reactions or side effects from medicines and adverse incidents involving medical equipment relating to COVID-19 treatment.
NEW – MHRA have a new biological reagent available to laboratories around the UK and the world that will help them to set up and develop accurate diagnostic tests for COVID-19. The reagent is intended to be used in tests that confirm whether an individual is currently infected with the virus.
UPDATED – additional information on additional pharmacovigilance and medical devices regulatory flexibilities.
Click here to read the bulletin in full.